Pfizer in new vaccine supply agreement with US; what does that mean?

Pharmaceutical giant Pfizer


PFIZER
+3.09%




closure:0

opening:51.76

High:52.79

low:51.09

cycle:

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




And its partner BioNTech


BIONTECH SE ADR
+8.15%




BIONTECH SE ADR


closure:0

opening:146.53

High:153.8

low:142.1

cycle:

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




Reportedly signed a $ 3.2 billion deal with the U.S. government for 105 million doses of their corona virus vaccine, which will be delivered in late summer and the fourth quarter of this year.

The price at which the deal was made, $ 30.48 per serving, represents an increase of 27% compared to $ 24 per serving paid by the US to Pfizer and BioNTech for 200 million rations in July 2021. The price is also 56% higher than the price of $ 19.50 per serving paid by the US For the initial order of 100 million packages in July 2020.

The news came a day after US Food and Drug Administration (FDA) consultants voted in favor of updating the booster vaccine, to specifically protect against the Omicron strain. Now, the deal may teach about a particular advantage of Pfizer over modernity


MODERN
+1.58%




MODERN


closure:0

opening:143.4

High:147.32

low:135.52

cycle:

Page Quote News Graphs Company Profile Recommendations


More articles on the subject:




In the fall vaccine market this fall since the latter has yet to announce a similar deal with the U.S. government. The updated vaccine may last until early November.

Wall Street analysts now expect a sharp drop in Corona vaccine revenue for Pfizer, from $ 33.9 billion this year to $ 16.3 billion in 2023, and $ 7.5 billion in 2024. However, there are those who believe that the deal reported by the company could help build a counter-argument against the expected decline. This is because in addition to the 105 million packages that will be delivered this year, the deal includes an option for an additional 195 million packages, which may satisfy US demand for next year.

Pfizer said that as part of the deal, it will provide doses at all authorized and approved dosage levels, including for young and older children. The company said the deal may also include Omicron-specific vaccines, if approved by the FDA.

Along with the report on the completion of the deal, Pfizer reported that it had submitted to the FDA a request for approval of the drug it had developed for the treatment of Corona. Paxlovid did so after the company received approval for emergency use from the FDA last December. As of the end of May, the company says it has shipped 12 million doses of the drug. The group also repeated sales estimates for the drug, which reach $ 22 billion.

Comments on the article(0):

Your response has been received and will be published subject to system policies.
Thanks.

For a new response

Your response was not sent due to a communication problem, please try again.

Return to comment

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick